精准肿瘤学、信号通路重编程和靶向治疗：一种整体性的分子癌症治疗方法

数据集获取（Figshare）

• 源站标题：<b>The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End</b>
• DOI：10.6084/m9.figshare.28140365.v2
• 发布日期：2025-06-08
• 文件数：8 个
• 文件总体积：4.64 MB
• 源站页面：https://figshare.com/articles/dataset/_b_Precision_Oncology_Signaling_Pathways_Reprogramming_and_Targeted_Therapy_A_Holistic_Approach_to_Molecular_Cancer_Therapeutics_b_/28140365

命令行下载

curl -L -o "Supplementary File 1.pdf" "https://ndownloader.figshare.com/files/51537047"
curl -L -o "Supplementary File 2.pdf" "https://ndownloader.figshare.com/files/51537050"
curl -L -o "Supplementary File 3.pdf" "https://ndownloader.figshare.com/files/51537053"
curl -L -o "Supplementary File 4.pdf" "https://ndownloader.figshare.com/files/51537056"
curl -L -o "Tables and Figures..pdf" "https://ndownloader.figshare.com/files/51537059"
curl -L -o "Cancer Genes.pdf" "https://ndownloader.figshare.com/files/51537062"
curl -L -o "The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End_.pdf" "https://ndownloader.figshare.com/files/55206431"
curl -L -o "The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End_.docx" "https://ndownloader.figshare.com/files/55206437"

文件清单

• Supplementary File 1.pdf（122.81 KB）
• Supplementary File 2.pdf（120.04 KB）
• Supplementary File 3.pdf（188.23 KB）
• Supplementary File 4.pdf（193.21 KB）
• Tables and Figures..pdf（508.27 KB）
• Cancer Genes.pdf（418.39 KB）
• The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End_.pdf（1.59 MB）
• The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signaling Pathways Is a Means to an End_.docx（1.50 MB）

文件总体积 4.64 MB（源站 API 实测）。

数据说明

The TCGA Research Network started in 2005 has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein, and epigenetic levels and thereby provided reliable diagnostic and prognostic biomarkers for different cancer types since then. The presence of mutated genes is strongly correlated with cancer incidence, very specific causative genes or a small set of genes for most cancers have not been confirmed after decades of genomic studies. Nobel laureate James D. Watson opined at Cancer World 2013: "We can go ahead and sequence every piece of DNA that has ever existed, but I don’‘t think we’'ll find the Achilles heel of cancer. Importantly, it is not only necessary to associate genetic mutations with different cancers but also to work on the mechanism of action of mutagens by focusing on enzymes which could invariably mediate oncogenic transformations. For example, overexpression of the ribonucleotide reductase (RnR) enzyme which catalyzes the formation of deoxyribonucleotides from ribonucleotides necessary for cell division, is implicated in many forms of cancer and the genes for the components of the enzyme are often mutated, leading to hyperactivity of the enzyme. But there are instances indicating that cytoplasmic material rather than the karyoplast would be responsible for cellular transformation that might be better explained as a consequence of certain epigenetic modulation than purely genetic changes. RnR active site inhibitors have been developed accordingly to biophysically deactivate the enzyme when necessary, with positive results A comprehensive analysis of tumors based on their genomic studies must reveal the alterations in signaling pathways indicating patterns of vulnerabilities and the means to identify prospective targets for the development of personalized treatments and new combination therapies. In this regard, the Cancer Cell Map Initiative (CCMI), launched in 2015 by researchers at the University of California, San Francisco and the University of California, San Diego, allowed researchers to determine how hundreds of genetic mutations involved in a few types of cancer affect the activity of cer

许可

CC0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28140365.v2（source: https://figshare.com/articles/dataset/_b_Precision_Oncology_Signaling_Pathways_Reprogramming_and_Targeted_Therapy_A_Holistic_Approach_to_Molecular_Cancer_Therapeutics_b_/28140365）。